{
    "nct_id": "NCT04691817",
    "official_title": "A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy",
    "inclusion_criteria": "* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older\n* Prior exposure to at least 1 line of therapy\n* Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial\n* ECOG PS 0-2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of a driver mutation that is susceptible to targeted therapy\n* No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy\n* Other active invasive malignancy requiring ongoing therapy\n* Evidence of progressing or untreated brain metastases\n* Evidence or history of leptomeningeal disease\n* Uncontrolled tumor related pain\n* History of an autoimmune disease or IPF",
    "miscellaneous_criteria": ""
}